Purpose: The molecular pathogenesis of growth hormone-secreting pituitary adenomas is not fully understood. Cytogenetic alterations might serve as alternative driver events in GNAS mutation-negative somatotroph tumors.
G rowth hormone (GH)-secreting pituitary adenomas are responsible for chronic GH excess leading to gigantism during childhood and acromegaly in adulthood. Pituitary adenomas appear to have a monoclonal origin, arising from either early progenitor cells or fully differentiated hormone-expressing cells (1, 2) , but their genetic background is not fully documented. Activating somatic mutations of the GNAS gene, which codes for the G protein-activating a subunit, promote tumor development and GH hypersecretion in ;30% of somatotroph adenomas (3) . No tumor-causing mutations in GH-secreting adenomas without GNAS mutations have been identified, apart from the rare cases due to germline mutations in AIP, MEN1, CDKN1B, or PRKR1A (4-11).
Cytogenetic or epigenetic alterations could serve as alternative driver events in GNAS mutation-negative pituitary tumors (12) . Recently, germline or somatic microduplications of chromosome region Xq26.3 containing the GPR101 gene were implicated in X-linked acrogigantism (13, 14) . This genomic gain in Xq26. 3 demonstrates that focal copy-number alterations (CNAs) can promote pituitary tumorigenesis. Several studies using oligonucleotide-based array comparative genomic hybridization (array-CGH) (15) (16) (17) (18) and, more recently, next-generation sequencing techniques (9, 10, 19) have shown various profiles of somatic CNAs in different subtypes of pituitary tumors. Given the large number of molecular alterations, it is important to distinguish between changes contributing to tumorigenesis and those that are nonfunctional byproducts. Large-scale sequencing suggests a higher degree of genomic disruption in hormonally active adenomas (19) . Only one recent study focused on genomic alterations specifically in 12 samples of GH-secreting adenomas (9) .
Here, we report the results of cytogenetic profiling based on array-CGH analysis in a large and wellcharacterized collection of 43 GH-secreting pituitary adenomas derived from patients with gigantism or acromegaly. We aimed at identifying specific patterns of chromosomal alterations that might reflect biological and molecular differences among these tumors, especially as a function of GNAS mutation status. We distinguished two groups of tumors based on the degree of genome disruption. We further studied copy-number oscillations compatible with chromothripsis in two adenomas, one from an AIP mutation-positive patient with acromegaly and one from an AIP mutation-negative patient with gigantism. Using DNA fluorescence in situ hybridization (FISH), we explored intratumor DNA copy-number heterogeneity and obtained insights into the complex subclonal architecture of these tumors.
Materials and Methods

Patients
We analyzed pituitary adenoma samples derived from 43 patients who had undergone transphenoidal surgery for acromegaly or gigantism between 2009 and 2016. The diagnosis of acromegaly was based on the classical symptoms and clinical signs plus elevated age-adjusted IGF-1 concentrations and unsuppressed GH after an oral glucose tolerance test (OGTT) (20) . Gigantism was defined by excessively rapid growth for age in children or adolescents (.97th percentile), or a final height .2 standard deviations above normal for the French population, together with abnormal IGF-1 values for age and unsuppressed GH after an OGTT. GH immunoreactivity was confirmed histologically in all samples. Tumors were considered plurihormonal if they were immunopositive for one or more hormones besides GH. Clinical, biological, and morphological data (e.g., sex, age at diagnosis, GH and IGF-1 concentrations, and tumor size and invasion) were systematically collected. Based on pituitary magnetic resonance imaging, the adenomas were classified into microadenomas (maximum diameter, ,10 mm), macroadenomas (maximum diameter, 10 to 39 mm), and giant adenomas (maximum diameter, .40 mm). We also analyzed three control pituitary adenoma samples from AIP mutationpositive patients: two patients had ACTH-secreting pituitary adenomas, and one had a nonfunctioning pituitary adenoma. All patients gave written informed consent for genetic analyses.
DNA extraction
Genomic DNA was extracted from pituitary tumor samples by using the phenol-chloroform-isoamyl alcohol extraction method (21) . The concentration and quality of the extracted DNA were determined with a spectrophotometer (ND-1000; NanoDrop Technologies, Wilmington, DE) and evaluated by electrophoresis on 0.7% agarose gel.
DNA sequencing
All patients were screened for germline AIP and GPR101 mutations as previously described (22) . A genetic search for somatic activating mutations of GNAS was carried out in all pituitary tumor samples. The forward primer 5 0 -CAAATTG-ATGTGAGCGCTGT-3 0 and the reverse primer 5 0 -AGCATC-CTACCGTTGAAGCA-3 0 were used to amplify a region of 480 bp that includes the hotspot mutations in codons 201 and 227 of GNAS exons 7 to 9. The following polymerase chain reaction thermocycling conditions were used: initial denaturation at 94°C for 5 minutes, followed by 35 cycles of denaturation at 94°C for 30 seconds, annealing at 58°C for 1 minute and extension at 72°C for 1 minute, followed by a final extension step at 72°C for 7 minutes. Gene mutations were evaluated by conventional Sanger sequencing with an automated capillary sequencer (ABI PRISM 3730S Genetic Analyzer; Applied Biosystems, Foster City, CA). A subset of 500,000 reads from each Fastq file was aligned to the reference human genome hg19/GRCh37 with tophat2 (-p 24 -r 150 -g 2-library-type fr-firststrand) (23) . Fusions initially detected by TopHat2 were filtered using the TopHatFusion-post algorithm. Only the most reliable fusions were kept for further analysis (i.e., fusions that were validated by BLAST and with at least 10 pairs of read spanning and validating the fusion event).
Oligonucleotide-based array-CGH
DNA FISH
DNA FISH was performed on interphase nuclei from tumors 33 and 43, which had a chromothripsis profile. The following probes were used in accordance with the manufacturer's recommendations: SNRPN 15q11.2 (coupled with the 15q subtelomeric region (Cytocell; Amplitech, Compiègne, France) and subtelomeric probes specific for chromosomes 2p, 6p, 6q, 10q, and 11p (Vysis; Abbott Laboratories, Chicago, IL). Bacterial artificial chromosome clones RP11-91N9 (2q37.1), RP11-192G6 (10q25.1), RP11-482O1 (11q13.2, AIP gene), RP11-368H5 (11q25), and RP11-783O1 (15q21.3) were used in accordance with the manufacturer's recommendations (RainbowFISH; Amplitech).
Statistical methods
Continuous variables are expressed as mean 6 standard deviation if normally distributed or as the median (interquartile range). Normal distribution was assessed with the Shapiro-Wilk test. Categorical variables are expressed as counts and percentages. Quantitative data were analyzed with the nonparametric Mann-Whitney U test or with the Kruskal-Wallis test. Qualitative comparisons used the x 2 test or Fisher's exact test as appropriate. Statistical significance was assumed at P , 0.05. All statistical analyses used Prism 6 (GraphPad Software Inc.).
Results
Clinical features
The characteristics of the patients are summarized in Supplemental Table 1 . There were 29 men and 14 women. Mean age at diagnosis was 42 6 14 years. Four patients had nonsyndromic gigantism, and 39 had adult-onset acromegaly due to pure GH-secreting or plurihormonal adenomas. The mean age-adjusted IGF-1 level was 340 6 115% of the upper limit of normal.
Genetic mutations
Acromegalic patient 33 harbored a missense germline c.2T.C mutation in the AIP start codon that abrogated protein expression (24) . Acromegalic patient 36 harbored a germline c.924G.C mutation in GPR101 (22) . Somatic activating GNAS mutations were found in 13 pituitary tumors (30.2%). These heterozygous missense mutations were p.Arg201Cys in nine patients (69.2%) and p.Gln227Leu in four patients (30.7%).
Somatic CNA profiles
Somatic CNAs are described in detail in Supplemental Tables 2 and 3 . The most common abnormalities were arm-level losses of chromosomes 1, 15q, and 16 and extensive gains of chromosomes 5, 7, 10, 19, 20, and X ( Fig. 1A and Supplemental Fig. 1 ). Most chromosome arms showed strong evidence of preferential gain or loss but rarely showed both. Among the focal CNAs, recurrent microduplication in 10p11.22 was found in 20 tumors, in addition to genomic gain of the entire arm of 10p in three patients (Fig. 1A) . The smallest regions of overlap (hg19 chr10: 33101459-33137499) encompassed one gene (CCDC7). Quantitative reverse transcription polymerase chain reaction quantification of CCDC7 transcripts showed no overexpression in samples with genomic gain in 10p11.22.
Array-CGH identified two distinct groups of tumors, based on the fraction of genome disruption, with significant quantitative and qualitative differences in the CNA profiles ( Fig. 1A and 2B ). Twenty-seven tumors (63%) had a low level of genomic disruption with total CNAs affecting ,12% of the genome, and 16 tumors (37%) had a high level (total CNAs $24%) of genomic disruption (10, 19) . The number of CNAs ranged from 0 to 51 per tumor in the low-CNA group and from 15 to 78 per tumor in the high CNA group. Losses predominated in the low-CNA group, whereas gains predominated in the high-CNA group (Fig. 1C) . Tumor 2 showed only genomic gains. Extensive arm-level chromosome alterations were more frequent in the high-CNA group (Fig. 1D) . No differences across the two groups were observed in terms of clinical features, pretreatment IGF-1 concentration, tumor size, invasive behavior, and Ki76 proliferation index. However, patients who displayed a paradoxical response of GH to oral glucose load during an OGTT harbored adenomas that belonged in the majority to the high-CNA group. In addition, plurihormonal tumors were more frequent in the groups with low numbers of somatic CNAs, and a densely granulated histotype was more prevalent in the high CNA group. All the GNAS mutation-positive tumors belonged to the low-CNA group, and no GNAS mutations were identified in the high-CNA group (Table 1 and Supplemental Table 1 ).
Identification and characterization of chromothripsis in two pituitary tumors
Adenoma samples from patients 33 ( Fig. 2) and 42 ( Fig. 3) showed multiple noncontiguous CNAs compatible with chromothripsis. Chromothripsis is a phenomenon whereby tens to hundreds of clustered chromosomal rearrangements (gains and deletions) involving localized genomic regions generating frequent oscillations between two copy-number states can be acquired in a oneoff cellular catastrophe (25) . Neither of these patients had received radiotherapy prior to surgery.
Patient 33 is a 42-year-old woman carrying a germline c.2T.C AIP mutation and a mixed GH-and PRLsecreting adenoma. Chromothripsis was observed on the long arm of chromosome 10 in its distal region (10q23.33q26.3) and included 39 CNAs (21 gains and 18 losses) and at least 78 breakpoints ( Fig. 2A and 2B ). Ratio plots suggested that chromothripsis was present in a mosaic state. A deletion of 40.5 Mb was also detected in the terminal region 10q23.33q26.3, suggesting instability in this region. No hallmarks of chromothripsis were identified in the patient's germline DNA. In addition, no chromothripsis-related pattern was identified in pituitary adenoma samples from three patients harboring germline AIP mutations.
Patient 42 is a 17-year-old man with acromegalogigantism due to an invasive GH-secreting macroadenoma. The genetic search for AIP and GPR101 mutations and Xq26 microduplication was negative. Chromothripsis was detected on the distal long arm of chromosome 2 (region 2q35q37.3), the distal short arm of chromosome 11 (region 11p15.5p15.4), the long arm of chromosome 11 (region 11q13.3q25), and the whole long arm of chromosome 15 ( Fig. 3A and 3B ). It included eight CNAs (two gains and six losses) and 16 breakpoints in 2q35q37.3, four CNAs (four losses) and eight breakpoints in 11p15.5p15.4, 17 CNAs (6 gains and 11 losses) and 33 breakpoints in 11q13.3q25, and 18 CNAs (one gain and 17 losses) and 34 breakpoints in chromosome 15. Ratio plots also indicated mosaicism. A deletion of 25.5 Mb was detected in the terminal region 2q34q37.3, Monosomy of the AIP locus 11q13 (red pinpoints) and of the chromothripsis-affected region 10q25.1 (green pinpoints) were seen in 58% and 26% of adenoma cells, respectively. As for the terminal region of the long arm of chromosome 10 (red pinpoints) neighboring the chromothripsis-affected region, 71% of cells showed disomy, whereas monosomy and trisomy were seen in 19% and 10%, respectively, of interphase nuclei. Finally, FISH analysis of the terminal region of the short arm of chromosome 2 (green pinpoint), whose array-CGH ratios suggested mosaicism, showed one locus in 62% of cells, two loci in 21%, three loci in 5%, and no 2p ter loci in 12%.
indicating instability of this region. Chromothripsis was absent in the patient's germline DNA.
Gene cartography of chromothripsis-related CNAs in both these tumors included a number of genes described in http://cancer.sanger.ac.uk/census/. These changes include amplification of oncogenes such as TLX1, FGFR2, and TCF7L2; loss of tumor-suppressor genes such as SUFU and VENTX; and deletions of genes involved in chromosome segregation and DNA crosslink repair such as BARD1, DCLRE1A, HDAC4, PAX3, SMC3, and XRCC5. Chromothripsis at chromosome 15q led to loss of the USP8 gene (26) .
To explore the consequences of chromothripsis, we performed RNA sequencing on the two concerned adenoma samples. A total of 17 fusion transcripts were identified and summarized in Supplemental Table 4 . None of the transcripts was previously reported in the Catalogue of Somatic Mutations in Cancer (http://cancer. sanger.ac.uk/cosmic/fusion) or in The Atlas of Genetics and Cytogenetics in Oncology and Haematology (http:// atlasgeneticsoncology.org/index.html). In tumor sample 33, seven fusion transcripts were identified. All were intrachromosomal, and five involved gene partners on chromosomes affected by chromothripsis. Two fusion transcripts were predicted to be in-frame, with both involving the TCERG1L gene as a partner gene.
TCERG1L has not been previously reported as a fusion gene partner with any other gene. Tumor 42 displayed 10 fusion transcripts. Four were intrachromosomal, and six were interchromosomal. Seven fusion transcripts were generated by chromothripsis. None of these fusions was predicted to be in frame.
Further characterization of chromothripsis and DNA copy-number heterogeneity
To further study the chromothripsis-related loci, we used DNA FISH to visualize chromosome segments at a single-cell level. In the tumor from patient 33, we analyzed two regions of chromosome 6 as controls. DNA FISH visualized two loci of the terminal segment of chromosome 6p in 100% of adenoma cells and one locus of the terminal segment of chromosome 6p in 50% of adenoma cells, consistent with the arm-level 6q deletion detected with array-CGH. Because this tumor was from an AIP mutation carrier, we further analyzed the 11q13 locus and identified loss of heterozygosity (LOH) at 11q13 in 58% of adenoma cells. Monosomy of 10q25.1 locus, affected by chromothripsis, was detected in 26% of cells. Four different cell populations coexist in this tumor, with either monosomy or disomy at one or both of the examined loci (Fig. 2C) . This cellular heterogeneity was further confirmed when studying the 2p and 10q terminal Two loci in the terminal region of the short arm of chromosome 2 with no CNAs (green pinpoints) and from the terminal region of the long arm of chromosome 2 (red pinpoints) affected by chromothripsis, were visible in 100% (positive control) and 75% of adenoma cells, respectively. We analyzed the terminal region of the short arm of chromosome 11 (green pinpoints) and the 11q25 locus (red pinpoints), both affected by chromothripsis. The former presented a complex pattern, with 0, 1, 2, and 3 visible loci in 12%, 32%, 14%, and 42% of adenoma cells, respectively, whereas the latter showed monosomy in 18% of cells and disomy in 82% of cells. FISH analysis of the 15q21.3 locus (red pinpoints) and the terminal region of the long arm of chromosome 15 (green pinpoints), both affected by chromothripsis, showed monosomy in 45% and 80% of cells, respectively. The 2pter locus (green pinpoints) again served as a control, in addition to the 15q11.2 locus (red pinpoints), both regions being devoid of CNAs. Both showed two pinpoints in all interphase nuclei.
regions. Six different cell populations were distinguished, with various combinations of CNAs ranging from nullosomy to trisomy (Fig. 2C) . In the tumor from patient 42, in accordance with the array-CGH findings, DNA FISH showed two loci of the terminal segment of chromosome 2p in all adenoma cells. Chromothripsis resulted in loss of the 2q37.1 locus in 25% of adenoma cells. Loss of the 15q21.3 locus and of the terminal segment of chromosome arm 15q was detected in 45% and 80% of cells, respectively, whereas two loci of region 15q11.2, which was unaffected by chromothripsis, were detected in all adenoma cells. Regarding chromosome 11, DNA FISH revealed the coexistence of six different cell populations, with CNAs ranging from nullosomy to trisomy, in the 11p terminal segment, together with monosomy or disomy at the 11q25 locus, both of which were affected by chromothripsis (Fig. 3C) .
DNA copy numbers determined by DNA FISH were in agreement with the array-CGH log ratios, which reflect the sum of CNAs occurring at a concerned locus.
Discussion
Several recent studies using next-generation sequencing methods have failed to discover new tumor-causing gene mutations in GNAS mutation-negative pituitary adenomas (9) (10) (11) 19) , thus pointing to a role of alternative oncogenic driver events, including cytogenetic alterations. Here, we describe the results of a combined cytogenetic search using array-CGH and DNA FISH in a large and well-characterized collection of GH-secreting pituitary adenomas from 43 patients with gigantism or acromegaly.
Based on the copy-number profiles, we found that 63% had CNAs involving ,12% of the genome, and the remaining 37% had disruption affecting 24% to 45% of the genome. None of the tumors presented disruptions affecting 12% to 24% of their genome. These findings are in agreement with Bi et al. (19) and Song et al. (10) , who similarly identified two groups of pituitary adenomas (including all histotypes) based on the degree of genomic disruption.
As previously reported (19, 27) , arm-level CNAs were the most common abnormalities. Such chromosome armlevel aberrations usually result from missegregation during anaphase at the level of the centromere (28) . This high rate of extensive chromosome alterations among genomically disrupted pituitary adenomas (which are invariably benign) exceeds that observed in several types of cancer (27) . Gains and losses were equally prevalent in the low-CNA group, whereas gains predominated with the highly disrupted group. Unlike in malignancies (29) , the frequency of arm-level CNAs was not related to the length of the chromosome arm. On the contrary, focal amplifications or deletions were rare, with the exception of 10p11.22 microduplication that was found in 20 adenomas, including four adenomas from the low-CNA group. This duplication encompassing CCDC7 gene was not associated with increased gene expression. The presence of this microduplication in almost half of the tumors suggests that it might be a benign, previously unreported copy-number variation.
These two groups of tumors classified according to the degree of genome disruption did not significantly differ with respect to tumor size, invasiveness, proliferative index, or surgical outcome. However, a paradoxical response of GH to oral glucose load and a densely granulated histotype were more frequent in the high-CNA group, highlighting that particular phenotype of these tumors. In addition, all 13 tumors harboring GNAS mutations belonged to the low-CNA group. Thus, two distinct molecular subclasses could be distinguished on the basis of GNAS mutation status and the degree of genome disruption. The GNAS mutationpositive adenomas had few CNAs, highlighting the oncogenic potency of constitutive GNAS activation (3), which by itself drives tumor growth and GH hypersecretion. GNASmutation-negative adenomas with a high degree of genomic disruption have a specific molecular pathogenesis. Given the large number of extensive genome disruptions in these tumors, it remains to be established whether (some) alterations are driving tumorigenesis or are just nonfunctional byproducts that accumulate during tumor development (29) .
Amplification of chromosome arm 20q, which contains the GNAS locus, was observed in 12 adenomas. As previously reported, none of these tumors with 20q duplication harbored a GNAS mutation, suggesting that genomic gain in 20q could be an alternative mechanism of GNAS activation in mutation-negative GH-secreting pituitary adenomas (27) .
Analysis of somatic structural variants revealed two tumors with complex chromosomal rearrangements compatible with chromothripsis. A key feature of chromothripsis is the formation of ten to hundreds of locally clustered DNA rearrangements through a single, cataclysmic event. Chromosomes affected by chromothripsis show a characteristic pattern of copy-number oscillations, whereby typically only two or occasionally three copy-number states are detectable along the chromosome in the context of a large number of rearrangements (25, 30) . Several mechanisms, including ionizing radiation, premature chromosome compaction, DNA replication stress, telomere shortening, aborting apoptosis, TP53 mutations, micronuclei collapse, and hyperploidy formation, have been implicated (30) (31) (32) . Although chromothripsis has mainly been described in malignant tumors and linked to aggressive behavior and poor patient survival, similar massive DNA rearrangements have been reported in benign uterine leiomyomas (33) . Chromothripsis-like patterns of CNAs were recently described in a GH-secreting adenoma harboring a GNAS mutation (9) and in a TSH-secreting adenoma (34) . We observed massive DNA rearrangements resulting from chromothripsis in an adenoma from an AIP mutationpositive patient with acromegaly, localized on the long arm of chromosome 10, and in an adenoma from an AIP mutation-negative patient with gigantism, involving chromosome arms 2q, 11p, 11q, and 15q. The regions affected by chromothripsis contained several simultaneous tumorigenic DNA alterations, including oncogene amplification, loss of tumor suppressor genes, and deletion of genes involved in chromosome segregation and DNA crosslink repair. RNA sequencing and analysis of fusion transcripts did not identify gene fusions with oncogenic potential. Two fusion transcripts were predicted to be in frame and therefore potentially functional if translated, both of which had TCERG1L as a gene fusion partner. TCERG1L is a transcription elongation regulator 1-like protein reported to be downregulated by hypermethylation in colon primary tumors. This gene has not been reported to be partnered with any other genes (35) .
Because ratio plots indicated that chromothripsis was present in a mosaic state, we applied DNA FISH to these tumor samples to analyze chromosome segments at the single-cell level. We found good concordance between the percentage of subpopulations visualized on DNA FISH and the log-ratios of CNAs observed by CGH. Contrary to some cancer types in which rearrangement outcomes of chromothripsis are detectable in almost all cells (25, 31) , we found rearrangements related to chromothripsis solely in tumor subclones of the two pituitary adenomas analyzed here. As also demonstrated in the case of a GNAS mutation-positive GH-secreting adenoma described by Valimaki et al. (9) , chromothripsis-related alterations in pituitary tumors are very unlikely to be tumor-initiating events; rather, they confer a growth advantage.
Genomic instability is an important source of diversified cell populations, resulting in intratumor heterogeneity (36) . DNA copy numbers detected in our FISH experiments distinguished up to six distinct cell subpopulations, demonstrating extensive intratumor genetic diversity in GH-secreting pituitary tumors, that are considered monoclonal in origin (1, 2) . This subclonal architecture of GH-secreting pituitary adenomas, previously reconstructed from sequencing data (9), provides certain insights into tumorigenesis. In the tumor from an AIP mutation-positive patient, LOH of 11q13 was detected in 58% of cells, rearrangements derived from chromothripsis on chromosome arm 10q were identified in 26% of cells, and the two alterations coexisted in 20% of cells. The precise dynamics of these chromosomal changes during tumor evolution remain to be determined. However, 11q13 LOH appears to be a late event, suggesting that biallelic AIP inactivation is not a prerequisite for AIP-related tumorigenesis. Because intratumor genetic heterogeneity results in phenotypic diversity, the subclonal architecture of pituitary tumors should be taken into account when studying the pathophysiology and dynamics of tumor evolution, tumor behaviors such as invasiveness and aggressiveness, and the variability of therapeutic responses (36, 37) .
Our study has some limitations. Cross-contamination from normal tissue of the adenoma samples cannot be completely excluded particularly in the microadenomas. However, 89% of adenomas included in this study were macroadenomas (Table 1) , and tumor sampling was performed by highly experienced neurosurgeons, thus minimizing the risk of contamination. Furthermore, because densely granulated adenoma histotype was more prevalent in the high CNA group, better responses to somatostatin analogs would be expected in this group (38) . However, responses to somatostatin analogs treatment could not be assessed due the small number of treated patients.
In summary, molecular stratification of GH-secreting pituitary adenomas based on the degree of genome disruption can divide them into low-and high-CNA groups. Driving GNAS mutations are associated with lesser genomic disruption, whereas some GNAS mutationnegative tumors exhibit a high degree of predominantly arm-level chromosomal alterations. We identified chromothripsis-related chromosome CNAs in two tumors resulting in fusion transcripts, along with extensive intratumor DNA copy-number heterogeneity, thereby revealing the complex and heterogeneous clonal landscape of GH-secreting pituitary adenomas. Whether the molecular stratification based on CNAs represents a new prognostic tool remains to be determined
